Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of PKN605 in adults with atrial fibrillation
NL-OMON60849Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of PKN605 in Atrial fibrillation (AFib), sponsored by Novartis. Started Jan 2026; status: recruiting.
02
Drugs
PKN605
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NL-OMON60849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60849.